Patents Issued in June 12, 2007
  • Patent number: 7229594
    Abstract: The invention provides a device for dispensing accurately-controlled small quantities of at least one liquid, comprising a liquid supply (L); a gas supply (G), arranged to selectively supply a gas pressure; and a capillary duct (20) adapted to be filled with liquid to be dispensed, and to eject the liquid. The device has a filling configuration wherein liquid from the supply is in contact with an end (20a) of the capillary duct to fill the capillary duct with liquid; and a liquid separation and ejection configuration, in which liquid remaining in the liquid supply is separated from liquid that fills the capillary duct to form a discrete quantity (V) of liquid filling the capillary duct (20) out of contact with the remaining liquid of the liquid supply. The capillary duct, filled with this discrete quantity (V) of liquid then has one end in contact with the gas supply and another end in contact with the atmosphere.
    Type: Grant
    Filed: April 3, 2001
    Date of Patent: June 12, 2007
    Assignee: Parabol Technologies S.A.
    Inventors: Philippe Renaud, Alain Donzel
  • Patent number: 7229595
    Abstract: This relates to filter columns for isolating nucleic acids. The filter column is adapted for stable placement within the upper portion of standard plastic collection tubes of various sizes. The body of the filter column has a number of surfaces to accommodate placement within variously sized collection tubes. The filter column contains nucleic acid-specific filter which can be located at alternate regions within the filter column, providing different filter surface areas and loading volume capacities using the same column body. The filter column has an opening on an upper end adapted to be sealed by a cap. A method for recovering nucleic acids using such filter column is also provided.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: June 12, 2007
    Assignee: Molecular Devices Corporation
    Inventors: Derrick A. Richardson, Derek S. Pai, Jorge Monteon
  • Patent number: 7229596
    Abstract: The Rh content by percentage in an HC absorbent catalytic converter provided in an exhaust pipe is greater than the Rh content by percentage in an upstream three-way catalyst. In this way, even when HC which has been temporarily absorbed is emitted in an atmosphere and the exhaust gas becomes rich, the HC absorbent catalytic converter displays improved oxidization and removal of HC due to the high content by percentage of Rh which has a high HC conversion ratio in rich atmospheres. There is no necessity to control the air-fuel ratio to a strongly lean ratio and so HC removal can be improved while maintaining suppression of NOx emissions.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: June 12, 2007
    Assignee: Nissan Motor Co., Ltd.
    Inventors: Hidetoshi Ito, Kimiyoshi Nishizawa, Ritsuo Sato
  • Patent number: 7229597
    Abstract: Provided is an emission treatment system and method for simultaneously remediating the nitrogen oxides (NOx), particulate matter, and gaseous hydrocarbons present in diesel engine exhaust streams. The emission treatment system has an oxidation catalyst upstream of a soot filter coated with a material effective in the Selective Catalytic Reduction (SCR) of NOx by a reductant, e.g., ammonia. Also provided is a method for disposing an SCR catalyst composition on a wall flow monolith that provides adequate catalyst loading, but does not result in unsuitable back pressures in the exhaust.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: June 12, 2007
    Assignee: BASFD Catalysts LLC
    Inventors: Joseph Allan Patchett, Joseph Charles Dettling, Elizabeth Alina Przybylski
  • Patent number: 7229598
    Abstract: A honeycomb body, which is composed in such a manner that a strip of corrugated foil made of heat-resistant stainless steel containing aluminum and a strip of flat foil made of stainless steel are alternately wound or laminated on each other, is incorporated into an outer cylinder made of metal and integrated into one body by means of diffusion bonding, so that a diffusion bonded metallic catalyst carrier can be formed. Surface roughness of the strip of foil after the completion of diffusion bonding is 0.001 to 2.0 ?m when it is expressed by center line average height Ra, and no sintered bridges are formed at both end portions of the diffusion bonded section in the longitudinal direction. The catalyst carrier is manufactured in a condition so that ?b, which is defined by ?b=6.
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: June 12, 2007
    Assignee: Nippon Steel Corporation
    Inventors: Yasuo Takahashi, Tadayuki Otani, Kazutoshi Iwami, Masayuki Kasuya
  • Patent number: 7229599
    Abstract: A container for holding powdered reagents that interact with water to form an anti-microbial fluid for use in an apparatus for cleaning and microbially deactivating items. The container includes a fluid inlet connectable to a source of water on an apparatus for cleaning and microbially deactivating items and a fluid outlet in fluid communication with items to be microbially deactivated. A continuous fluid passage is defined through the container between the fluid inlet and the fluid outlet. A plurality of spaced-apart barrier elements are disposed within the fluid passage to define a plurality of isolated compartments within the container. The barrier elements are impervious to powdered reagents, but permeable to the chemical reagents when dissolved in a liquid. A first dry, powdered reagent is disposed within one of the compartments for forming an anti-microbial solution when water flows through the container.
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: June 12, 2007
    Assignee: Steris Inc.
    Inventors: Jeffrey R. Horacek, Christopher A. Jethrow
  • Patent number: 7229600
    Abstract: Rare earth compositions comprising nanoparticles, methods of making nanoparticles, and methods of using nanoparticles are described. The compositions of the nanomaterials discussed may include scandium (Sc), yttrium (Y), lanthanum (La), cerium (Ce), praseodymium (Pr), neodymium (Nd), promethium (Pm), samarium (Sm), europium (Eu), gadolinium (Gd), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), thulium (Tm), ytterbium (Yb), and lutetium (Lu). The nanoparticles can be used to make organometallics, nitrates, and hydroxides. The nanoparticles can be used in a variety of applications, such as pigments, catalysts, polishing agents, coatings, electroceramics, catalysts, optics, phosphors, and detectors.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: June 12, 2007
    Assignee: NanoProducts Corporation
    Inventor: Tapesh Yadav
  • Patent number: 7229601
    Abstract: A process for reclaiming ammonia from waste streams comprises reacting at least one waste stream with an excess of hydroxide to produce ammonia and water. The ammonia is removed from the reaction vessel and purified.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: June 12, 2007
    Assignee: SEH-America, Inc.
    Inventor: Brian L. Tansy
  • Patent number: 7229602
    Abstract: A method of preparing metal chalcogenide particles. The method comprising the step of reacting an amine and metal complex precursors. The metal complex precursors comprising a chalcogenide and an electrophilic group. The reaction forming metal chalcogenide particles substantially free of the electrophilic group.
    Type: Grant
    Filed: June 4, 2004
    Date of Patent: June 12, 2007
    Assignee: National University of Singapore
    Inventors: Wee Shong Chin, Zhihua Zhang, Wen Pei Lim
  • Patent number: 7229603
    Abstract: A novel method is set out of preparation of radioactive diagnostic radiopharmaceutical in a stable, shippable, lyophilized form by an apparatus designed to rapidly flash freeze and dehydrate a radiopharmaceutical composition to minimize auto radiolysis. The method proposes rapid cooling and removal of ambient vapor, and then ultra cold removal when the potential of explosive liquid oxygen is eliminated. The radioactive diagnostic radiopharmaceutical requires no further cold or refrigerated storage, including with respect to shipping, subsequent to stabilization. The preferred composition can be reconstituted “on site” by the addition of a suitable diluent to bring the radiopharmaceutical complex into solution at a desired concentration.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: June 12, 2007
    Assignee: AnazaoHealth Corporation
    Inventors: John H. Kuperus, Robert G. McKenzie, Jr., Brooke Schumm, III
  • Patent number: 7229604
    Abstract: The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.
    Type: Grant
    Filed: September 26, 2003
    Date of Patent: June 12, 2007
    Assignee: Board of Regents, The University of Texas System
    Inventors: David J. Yang, Chun W. Liu, Dong-Fang Yu, E. Edmund Kim
  • Patent number: 7229605
    Abstract: Methods for determining the effect of a Clostridial neurotoxin on muscle are disclosed. In particular, methods for determining a potency and/or diffusion of a neurotoxin based on a nuclear index and/or an amount of muscle atrophy are disclosed. The methods may be used to distinguish two different Clostridial neurotoxins. In certain embodiments, the neurotoxins are obtained from Clostridium botulinum.
    Type: Grant
    Filed: August 13, 2004
    Date of Patent: June 12, 2007
    Assignee: Allergan, Inc.
    Inventors: James M. Holland, Edward Chow
  • Patent number: 7229606
    Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
    Type: Grant
    Filed: January 12, 2004
    Date of Patent: June 12, 2007
    Assignee: Epix Pharmaceuticals, Inc.
    Inventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer
  • Patent number: 7229607
    Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.
    Type: Grant
    Filed: October 7, 2002
    Date of Patent: June 12, 2007
    Assignee: Sosei R&D Ltd
    Inventors: Robin Mark Bannister, Andrew John McGlashan Richards, Julian Clive Gilbert, David A. V. Morton, John Staniforth
  • Patent number: 7229609
    Abstract: Novel 4,4-diarylbutadiene-substituted methyltrialkylsilanes having the structural formula (I): are useful sunscreens for UV-photoprotecting human skin against the damaging effects of UV-radiation, notably UV-A radiation.
    Type: Grant
    Filed: November 24, 2004
    Date of Patent: June 12, 2007
    Assignee: L'Oreal
    Inventor: Herve Richard
  • Patent number: 7229610
    Abstract: Novel 4,4-diarylbutadiene-substituted diorganopolysiloxanes having the structural formulae (1) or (2): in which A is a radical of formula (3) below: are useful sunscreens for UV-photoprotecting human skin against the damaging effects of UV-radiation, notably UV-A radiation.
    Type: Grant
    Filed: November 24, 2004
    Date of Patent: June 12, 2007
    Assignee: L'Oreal
    Inventor: Herve Richard
  • Patent number: 7229611
    Abstract: Disclosed are clear antiperspirant or deodorant compositions that include visible capsules.
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: June 12, 2007
    Assignee: The Gillette Company
    Inventors: Jose F. Zamudio-Tena, Gordon G. Guay, Tuan M. Vu, John Anderson
  • Patent number: 7229612
    Abstract: The present invention related to compositions (deodorizing or not) for human and animal excrement, especially pest and livestock, comprised of acidic agents and water soluble polymers, wherein the acidic agents are base neutralizers for the ammonia and indolic amines in the excrement and the water soluble polymers are barrier forming agents for the vapor of the offensive odor producing compounds in the excrement and for slowing down the air oxidative and enzymatic nitrification of the excrement ammonia and organic nitrogen thus dispersing the attenuating nitrate concentrations in the environment. The present invention further relates to a method of applying said compositions to excrement. Said compositions may be applied to excrement in liquid form by mixing the liquid composition together with the excrement, or in the form of a spray, by spraying the composition directly onto the excrement.
    Type: Grant
    Filed: March 4, 2002
    Date of Patent: June 12, 2007
    Assignee: Damar Holdings S.A.
    Inventors: Shalom Levi, Steve Daren
  • Patent number: 7229613
    Abstract: A method for treating hyperglycemia and/or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment, the amine polymer is aliphatic. Examples of polymers useful in an embodiment of the invention include sevelamer hydrogen chloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula: and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that lowers serum glucose.
    Type: Grant
    Filed: April 17, 2002
    Date of Patent: June 12, 2007
    Assignee: Genzyme Corporation
    Inventors: Steven K. Burke, Joanne M. Donovan
  • Patent number: 7229614
    Abstract: The present invention is directed to methods of treating or preventing angiomyolipomas by administering interferon gamma. It also encompasses methods for assessing the risk of a patient developing angiomyolipomas based upon interferon gamma expression.
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: June 12, 2007
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Sandra L. Dabora, David J. Kwiatkowski
  • Patent number: 7229615
    Abstract: A vaccine for in ovo vaccination against avian coccidiosis produced by a method including obtaining the coccidial oocysts from a fecal suspension, homogenizing the fecal suspension, separating the oocysts from the fecal debris by either salt flotation using sodium sulfate or gas flotation using air, sporulating the oocysts using hydrogen peroxide and air sparging, bleaching the sporulated oocysts, washing the bleached oocysts, concentrating the sterile washed oocysts and combining the concentrates of various species of coccidial oocysts, and producing a vaccine. The method in whole or in part can be applied to other kinds of encysted protozoa to produce vaccines for various types of animals.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: June 12, 2007
    Assignee: Pfizer, Inc.
    Inventors: Harold N. Conkle, Joseph E. Schultz, Scott J. Blonigen, Fred H. Weber, David R. Kilanowski, Bruce Monzyk, Timothy M. Werner, Chad M. Cucksey, Hamish A. I. McArthur, Ted L. Tewksbury
  • Patent number: 7229616
    Abstract: The present invention relates to the use of a supernatant of lactic acid bacteria or of Bifidobacteria capable of preventing colonization of intestinal cells by Giardia intestinalis, for the preparation of an ingestible carrier for the treatment and/or prophylaxis of disorders associated with the colonization of the gut by Giardia intestinalis. The present invention also pertains to specific strains of Bifidobacterium having the above traits and to the ingestible carrier, such as a food or pharmaceutical composition, containing such supernatant or the microorganisms.
    Type: Grant
    Filed: April 20, 2005
    Date of Patent: June 12, 2007
    Assignee: Nestec S.A.
    Inventors: Eduardo Schiffrin, Pablo Perez
  • Patent number: 7229617
    Abstract: Anti-DR4 or Anti-DR5 antibody agonists, combined with apoptosis-inducing agents, synergistically induce apoptosis in cancer cells.
    Type: Grant
    Filed: November 25, 2003
    Date of Patent: June 12, 2007
    Assignee: IRM LLC
    Inventors: Marc Nasoff, Quinn L. Deveraux, Deborah A. Knee, Pedro Aza-Blanc, Garret M. Hampton, Klaus Wagner
  • Patent number: 7229618
    Abstract: The present invention provides crystalline forms and three-dimensional atomic structure coordinates of Synagis Fab. The present invention further provides methods of using such three-dimensional atomic structure coordinates for designing and identifying Synagis binding agents. The present invention also provides machine readable media embedded with the three-dimensional atomic structure coordinates of Synagis Fab and methods of using them.
    Type: Grant
    Filed: August 17, 2005
    Date of Patent: June 12, 2007
    Assignees: Medimmune, Inc., Bowie State University
    Inventors: Leslie S. Johnson, Bradford Braden
  • Patent number: 7229619
    Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: June 12, 2007
    Assignee: MedImmune, Inc.
    Inventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins, Herren Wu
  • Patent number: 7229620
    Abstract: Methods and kits for radiolabeling proteins, peptides and ligands with radiolytic isotopes, particularly yttrium-90, are disclosed, whereby sufficient purity, specific activity and binding affinity are achieved such that the radiolabeled protein may be directly administered to a patient without further column purification. Such kits and methods will be particularly useful in bringing radioimmunotherapy to the hospital and outpatient setting for the treatment of cancer.
    Type: Grant
    Filed: July 15, 2005
    Date of Patent: June 12, 2007
    Assignee: Biogen Idec Inc.
    Inventor: Paul Chinn
  • Patent number: 7229621
    Abstract: The present invention is related to a method for enhancing the immunogenicity of an antigen in a mammal by introducing into the mammal an antigen or a portion thereof and administering to the mammal a treatment that increases antigen presentation in a lymphoid organ.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: June 12, 2007
    Assignee: Torrey Pines Institute for Molecular Studies
    Inventor: Carol O. Cowing
  • Patent number: 7229622
    Abstract: The present invention provides synthetic chimeric fimbrin peptides which induce an immunogenic response in animals to non-typable Haemophilus influenzae and that do not require tedious purification techniques. The synthetic chimeric fimbrin peptides reduce the severity of otitis media caused by Haemophilus influenzae. The synthetic chimeric fimbrin peptides are synthesized using commercially available peptide synthesizers. The synthetic chimeric fimbrin peptides comprises three peptide units. The first peptide unit is a subunit of the fimbrin protein. Preferably, the fimbrin subunit is comprised of the amino acids of Sequence ID No. 1 or Sequence ID No. 2. The second peptide unit is a t cell epitope, and preferably has the amino acid sequence of SEQ ID NO. 3. The third peptide unit is a linker peptide unit which joins the first and second peptide unit.
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: June 12, 2007
    Assignee: The Ohio State University Research Foundation
    Inventors: Lauren O. Bakaletz, Pravin T. P. Kaumaya
  • Patent number: 7229623
    Abstract: The present invention is generally directed to Her-2/neu fusion proteins, nucleic acid molecules encoding Her-2/neu fusion proteins, viral vectors expressing Her-2/neu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the Her-2/neu fusion proteins and/or nucleic acid molecules encoding the Her-2/neu fusion proteins. The present invention is also directed to methods of treating or preventing cancer by eliciting or enhancing an immune response to the Her-2/neu protein, including for uses in the treatment of malignancies associated with the Her-2/neu oncogene.
    Type: Grant
    Filed: August 3, 2000
    Date of Patent: June 12, 2007
    Assignee: Corixa Corporation
    Inventors: Martin A. Cheever, Dirk Gheysen
  • Patent number: 7229624
    Abstract: The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatment of allergies and the treatment of cancers. Various embodiments of the invention provide for a virus, virus-like particle, viral capsid particle, phage or recombinant form thereof coated with any desired antigen in a highly ordered and repetitive fashion as the result of specific interactions. In one specific embodiment, a versatile new technology based on a cassette-type system (AlphaVaccine Technology) allows production of antigen coated viral particles. Other specific embodiments allow the production of antigen coated hepatitis B virus-like particles or antigen coated Measles virus-like particles.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: June 12, 2007
    Assignee: Cytos Biotechnology AG
    Inventors: Wolfgang A. Renner, Frank Hennecke, Lars Nieba, Martin Bachmann
  • Patent number: 7229625
    Abstract: Non-infectious, retrovirus-like particles contain mutations to reduce gag-dependent RNA-packaging of the gag gene product, eliminate reverse transcriptase activity of the pol gene product, eliminate integrase activity of the pol gene product and eliminate RNase H activity of the pol gene product through genetic manipulation of the gag and pol genes. The corresponding nucleic acid molecules are described. The non-infectious, retrovirus-like particles have utility in in vivo administration including to humans and in diagnosis.
    Type: Grant
    Filed: April 22, 2005
    Date of Patent: June 12, 2007
    Assignee: Sanofi Pasteur Limited
    Inventors: Benjamin Rovinski, Shi-Xian Cao, Fei-Long Yao, Roy Persson, Michel H. Klein
  • Patent number: 7229626
    Abstract: Methods for treating psychiatric disorders include intracranial administration of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A, to a human patient.
    Type: Grant
    Filed: March 22, 2004
    Date of Patent: June 12, 2007
    Assignee: Allergan, Inc.
    Inventor: Stephen Donovan
  • Patent number: 7229627
    Abstract: Disclosed are apparatuses and methods for the production of attenuated aseptic parasites in hematophagous insects generally, and production of Plasmodium species sporozoites in Anopheles species mosquitoes specifically; apparatuses and methods for the production of strains of hematophagous insects with desired properties such as hypoallergenicity or hyperinfectivity; methods of producing a parasite strain that is capable of withstanding cyropreservation at temperatures close to freezing; apparatuses and methods for the injection of an attenuated parasite vaccine; production of parasites and hematophagous insects that are free from contamination by unwanted biological agents; apparatuses for the reconstruction of complex parasitic life cycles aseptically to avoid the contamination of the parasite or the insect vector host with unwanted biological agents.
    Type: Grant
    Filed: October 4, 2004
    Date of Patent: June 12, 2007
    Assignee: Sanaria, Inc.
    Inventors: Stephen L. Hoffman, Thomas C. Luke
  • Patent number: 7229628
    Abstract: T cell activation in response to antigen is increased by the administration of binding agents that block CTLA-4 signaling. When CTLA-4 signaling is thus blocked, the T cell response to antigen is released from inhibition. Such an enhanced response is useful for the treatment of tumors, chronic viral infections, and as an adjuvant during immunization.
    Type: Grant
    Filed: December 7, 1999
    Date of Patent: June 12, 2007
    Assignee: The Regents of the University of California, Office of Technology Transfer
    Inventors: James Patrick Allison, Dana R. Leach, Matthew E. Krummel
  • Patent number: 7229629
    Abstract: Carboxylic-gated-nitroxide (CGN) compounds and their esterified derivatives are discovered and disclosed as compositions and shown to have the potential in treating a variety of acute and chronic diseases and disorders resulting from reactive oxygen species (ROS) injury. Compositions for treating tissue damage from ROS injury containing CGN, or active derivatives thereof, in a suitable pharmaceutical, cosmetic, and diagnostic formulations are described.
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: June 12, 2007
    Assignee: SynZyme Technologies, LLC
    Inventors: Jen-Chang Hsia, Li Ma
  • Patent number: 7229630
    Abstract: The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: June 12, 2007
    Assignee: Novalar Pharmaceuticals, Inc.
    Inventors: Andrew X. Chen, Julius Knowles, Eckard Weber
  • Patent number: 7229631
    Abstract: The invention provides oil-in-water emulsions comprising recombinant collagen-like polymer in an amount sufficient to act as stabiliser of the emulsion. The polymer is especially a polypeptide which is free of helix structure, has an isoelectric point at least 0.5 pH units removed from the pH of the oil-in-water emulsion. Furthermore, amphiphilic recombinant collagen-like polymers are provided for use in oil-in-water emulsions. The amphiphilic polymers are polar at one end as a result of a relative abundance of polar amino acids, and apolar at the other end as a result of a relative abundance of apolar amino acids.
    Type: Grant
    Filed: September 26, 2003
    Date of Patent: June 12, 2007
    Assignee: Fuji Photo Manufacturing Europe B.V.
    Inventors: Joseph Hubertus Olijve, Jan Bastiaan Bouwstra, Frederik Anton Wolf De, Marc Willem Theodoor Werten, Hendrik Wouter Wisselink, Richéle Deodata Wind, Tanja Jacoba Bosch Van Den, Yuzo Toda
  • Patent number: 7229632
    Abstract: An emulsion having one oily outer phase, and two aqueous inner phases, one of which is a gel. The emulsion may be used for cosmetic, pharmaceutical, veterinary and detergent purposes.
    Type: Grant
    Filed: February 5, 2002
    Date of Patent: June 12, 2007
    Assignee: Societe d'Exploitation de Produits pour les Industries Chimiques-Seppic
    Inventors: Chantal Amalric, Alicia Roso, Nelly Michel
  • Patent number: 7229633
    Abstract: The present invention relates generally to the preparation and use of biological tissue adhesives which rely on combining fibrinogen and thrombin. More particularly, the present invention relates to a method of preparing a fibrin sealant whereby said sealant is formed by reconstituting the fibrinogen or the thrombin component in the presence of biological and/or non-biological agents such as drugs, chemicals, and proteins. Preferably, these agents are introduced in solution, such as for example, a corticosteroid-containing solution like a betamethasone solution containing betamethasone acetate or betamethasone sodium phosphate; a triamicinolone solution; or a methylprednisolone solution. These solutions may be substituted for, or provided as a complement to, other solutions that are typically used in the preparation of fibrin sealants such as, for example, calcium chloride.
    Type: Grant
    Filed: December 4, 2004
    Date of Patent: June 12, 2007
    Assignee: Spinal Restoration, Inc.
    Inventors: Sam L. Austin, Thomas E. Davis
  • Patent number: 7229634
    Abstract: The present invention provides engineered proteins and biomedical products made from the engineered proteins. The biomedical products include lenses useful for ophthalmic purposes.
    Type: Grant
    Filed: January 21, 2005
    Date of Patent: June 12, 2007
    Assignees: California Institute of Technology, The Regents of the University of California
    Inventors: David A. Tirrell, Daniel M. Schwartz, Paul J. Nowatzki, Robert H. Grubbs
  • Patent number: 7229635
    Abstract: The present invention is directed to a method of modulating the release of at least one endogenous compound in vivo. The method comprises delivering intranasally at least one micro-construct comprising an agonist and a pharmaceutically acceptable carrier to a locus comprising an agonist receptor and a heterologous receptor that is coupled to at least one common signaling molecule. The micro-construct used in the present inventive method provides sustained release of the agonist provided by erosion of an exterior surface defined by the micro-construct. Once released, the agonist effectively up- or down-regulates at least one signaling molecule common to both the agonist receptor and the heterologous receptor, thereby potentiating or desensitizing the heterologous receptor in order to modulate release of at least one endogenous compound under the control of the heterologous receptor.
    Type: Grant
    Filed: April 20, 2001
    Date of Patent: June 12, 2007
    Assignee: Indiana University Research and Technology Corporation
    Inventor: Michael J. Kubek
  • Patent number: 7229636
    Abstract: A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: June 12, 2007
    Assignee: Nastech Pharmaceutical Company Inc.
    Inventors: Steven C. Quay, Peter C. Aprile, Zenaida O. Go, Anthony P. Sileno
  • Patent number: 7229637
    Abstract: The invention relates to the food and medical industries, medical cosmetics, dermatology, agriculture and the mixed feed industry. According to the invention vicinal dithioglycole (common formula RCH(SH)CH(SH)R?1 (I)) is used as a food additive, a food product, physiologically-active substances and active ingredients of forage additives and of forage, in cosmetic and/or dermatological and skin-therapeutic remedies. The invention comprises methods for producing such additives, products and remedies. The substance of formula (I) stimulates physiological processes, increases human and animal immunity, inhibits undesirable process in organisms and food products, produces curative and preventive action of skin, hair and nails and after vicinal dithioglycole is administered the intoxication effect of alcohol consumption known as hang-over is completely remored.
    Type: Grant
    Filed: December 28, 2000
    Date of Patent: June 12, 2007
    Inventors: Sergei Mikhailovich Zenovich, Boris Khaimovich Strelets
  • Patent number: 7229638
    Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of a biopolymer.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: June 12, 2007
    Assignee: Artemis Proteomics, Ltd.
    Inventors: George Jackowski, Brad Thatcher, John Marshall, Jason Yantha, Tammy Vrees
  • Patent number: 7229639
    Abstract: The present invention relates to pharmaceutically acceptable and stable compositions, which are preferably clear transparent, for liquid filling hard shell capsules, hard shell capsules containing these compositions, and a process for preparing these hard shell capsules and whereby the shells of said hard capsules are preferably clear transparent.
    Type: Grant
    Filed: March 7, 2003
    Date of Patent: June 12, 2007
    Assignee: Warner-Lambert Company
    Inventors: Emmanuelle Mireille Guillard, Nicolas Madit, Robert Anthony Scott
  • Patent number: 7229640
    Abstract: A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxtine.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: June 12, 2007
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Graham Stanley Leonard, David Philip Elder
  • Patent number: 7229641
    Abstract: A novel rapid-melt composition, including methods of making the same, and methods of using the same for the delivery of prophylactic and therapeutic active materials to a mammal. The rapid-melt compositions are formed by molding or compression, with an additional heating step being preferred.
    Type: Grant
    Filed: August 1, 2002
    Date of Patent: June 12, 2007
    Assignee: Capricorn Pharma, Inc.
    Inventor: S. Rao Cherukuri
  • Patent number: 7229642
    Abstract: Disclosed herein is a oral extended release dosage form comprising a plurality of granules of an effective amount of a pharmaceutically active compound, at least one amino acid, and an intragranular polymer in which the granule is dispersed within a hydrophilic extragranular polymer matrix which is more rapidly hydrating than the intragranular polymer. The amino acid is selected for hydropathy characteristics depending on solubility characteristics of the active compound.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: June 12, 2007
    Assignee: Scolr, Inc.
    Inventors: A. Reza Fassihi, Thomas Dürig
  • Patent number: 7229643
    Abstract: The invention provides a pharmaceutically elegant solid oral formulation of olanzapine and a process for making such formulation.
    Type: Grant
    Filed: July 8, 2004
    Date of Patent: June 12, 2007
    Assignee: Eli Lilly and Company
    Inventors: George Randall Cochran, Tommy Clifford Morris
  • Patent number: 7229644
    Abstract: The present invention is related to compositions of modafinil, including compositions of modafinil and one or more diluents, disintegrants, binders and lubricants, and the processes for their preparation thereof.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: June 12, 2007
    Assignee: Cephalon, Inc.
    Inventors: Vincent Corvari, George Grandolfi, Alpa Parikh